GHK-Cu References

How to read this list

These GHK-Cu references are the full source set behind the digest. Each inline marker — ^[1], ^[2], and so on — corresponds to the numbered entry here. Identifiers (DOI, PMID, PMC) are given so any claim can be traced to its source. Every quantitative statement on this site — every dose, percentage, molecular weight and effect size — maps to one of these entries.

The record is weighted toward in-vitro and rodent work plus a set of reviews, several from one investigator group (Loren Pickart and colleagues, 1938-2023). That concentration of authorship is worth holding in mind when weighing the broad gene-expression and systemic anti-aging claims, which await wider independent replication. Independent contributions carry the strongest external corroboration: the COPD lung-fibroblast gene-signature study from Campbell and colleagues ^[8], the human skin-penetration measurement from Hostynek and colleagues ^[5], the 45-man hair-loss trial ^[4], the 2025 DSS-colitis study ^[14], and the 2024 CNS copper-aggregation work ^[15].

Two cautions run through the citations. Where a study used the free peptide GHK rather than the GHK-Cu copper chelate, that distinction is flagged in the text, because copper coordination is required for most of the documented matrix activity ^[1]. And the freshest anchors — a 2025 anti-wrinkle review ^[13], the 2025 colitis study ^[14] and the 2024 CNS study ^[15] — are included as the most recent synthesis of an otherwise mature literature. Reading any claim back to its source group is the fastest way to judge how much weight it can bear.